A Randomized Phase II, Multi-Center, Open-Label Trial of PR104 and Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs PR 104 (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Proacta
- 24 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Apr 2009 Lead trial investigator (Patel JD) added as reported by Robert H. Lurie Comprehensive Cancer Center, Northwestern University.